imatinib

imatinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Inherited Bone Marrow Failure Syndrome、Familial Platelet Disorder With Predisposition to Myeloid Malignancies。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 imatinib 研究

• Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

  I 期招募中美国NCT06090669

• KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

  II 期招募中美国NCT07406633

• A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

  III 期招募中美国Argentina澳大利亚BrazilNCT07585266

• A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

  不适用招募中美国NCT07091019

• Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)

  不适用招募中瑞典NCT05722795

• Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

  IV 期招募中中国NCT03844360

• A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

  不适用招募中德国NCT07549516

• Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

  II 期招募中美国NCT04598009

• Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

  不适用招募中EgyptNCT05282108

• Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study

  不适用招募中荷兰NCT07522762

• 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

  II 期招募中South KoreaNCT05385549

• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  II 期招募中美国澳大利亚加拿大Puerto RicoNCT06124157

• Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients

  I 期 / II 期招募中South KoreaNCT07096609

• A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

  II 期招募中美国比利时德国意大利NCT07124078

• Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

  不适用招募中美国NCT00816114

• Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

  II 期招募中德国NCT06061094

• Imatinib and Trametinib for KRAS-mutated Solid Tumor

  I 期招募中中国台湾NCT06962254

• A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib

  II 期招募中日本NCT07689201

• Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria

  II 期招募中KenyaNCT07559370

• COMPERA / COMPERA-KIDS

  不适用招募中比利时德国意大利瑞士NCT01347216

• Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

  II 期招募中美国NCT01746836

• Precision Cancer Therapy in Rare Cancers

  II 期招募中挪威NCT06119789

• Ma-Spore ALL 2020 Study

  II 期招募中MalaysiaSingaporeNCT06336395

• A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

  I 期招募中美国NCT06655246

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。